US EditionIsomorphic Labs Secures $600M to Advance AI-Powered Drug Discovery
- Isomorphic Labs, an AI-based drug discovery company spun out of Google DeepMind and based in London, raised $600 million in its first external funding round.
- Founded in 2021 by Sir Demis Hassabis to develop treatments for millions of patients worldwide, Isomorphic Labs leverages DeepMind's AlphaFold software to advance its AI drug design engine.
- This funding will accelerate research and development efforts, advance Isomorphic Labs' AI drug design engine, and support the company's internal drug pipeline focused on oncology and immunology, including small molecule programs developed through collaborations.
- Isomorphic Labs has collaborations with Eli Lilly and Novartis, potentially generating up to $3 billion in milestone payments; Eli Lilly paid $45 million upfront with potential milestone payments up to $1.7 billion, while Novartis paid $37.5 million upfront with potential milestone payments up to $1.2 billion, also agreeing last month to add three additional programs to their collaboration.
- Led by Sir Demis Hassabis, Isomorphic Labs expects to use the new capital to expand its staff, attract top-tier talent, advance its programs into clinical development, and potentially have AI-designed drugs in clinical trials by the end of 2025, furthering its mission to solve all disease with AI.
Insights by Ground AI
Does this summary seem wrong?
42 Articles
42 Articles
All
Left
3
Center
12
Right
4
Demis Hassabis on Isomorphic’s $600 million raise, AI, and healthcare’s future
What if it’s not "just a game"? In AI, games are more than just fun—they can reconceive what’s possible. Demis Hassabis, cofounder of DeepMind and 2024 Nobel Laureate, knows this firsthand. In 2016, after AlphaGo—the AI program developed to play the ancient Chinese game of Go—defeated world champion Lee Sedol, Hassabis saw a new horizon for AI. The victory wasn’t just about beating an 18-time international champion, it was a demonstration of AI…
·New York, United States
Read Full Article
TechCrunchReposted by 
Latest Nigerian News
Latest Nigerian NewsAlphabet's AI drug discovery platform Isomorphic Labs raises $600M from Thrive
Isomorphic Labs, the AI drug discovery platform that was spun out of Google's DeepMind in 2021, has raised external capital for the first time. The $600
·United States
Read Full Article
Coverage Details
Total News Sources42
Leaning Left3Leaning Right4Center12Last UpdatedBias Distribution63% Center
Bias Distribution
- 63% of the sources are Center
63% Center
L 16%
C 63%
R 21%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
